Fig. 1From: Third-line therapy for chronic myeloid leukemia: current status and future directionsTherapies in development vs approved therapies for CML in the 3L + setting. 3L third line, allo-SCT allogeneic stem cell transplant, ATP adenosine triphosphate, CML chronic myeloid leukemia, STAMP Specifically Targeting the ABL Myristoyl Pocket, TKI tyrosine kinaseBack to article page